GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

Segment wise Revenue, Results and Capital Employed, under Clause 41 of the Listing Agreement

(Rs. lakhs)

Audited

Unaudited

	Unaudited		Audited
	3 months	3 months	Year
	ended	ended	ended
	31.03.2007	31.03.2006	31.12.2006
Segment Revenue:			
a) Pharmaceuticals	39940	38065	141602
b) Other Businesses	3269	5322	18134
Total Segment Revenue	43209	43387	159736
Less: Inter Segment Revenue	-	-	-
Net Sales / Income from Operations	43209	43387	159736
Segment Results (Profit before Interest and Tax):			
a) Pharmaceuticals	15348	14181	49211
b) Other Businesses	702	950	3848
Total Segment Results	16050	15131	53059
Add/(Less):			
(i) Interest Income (net)	1009	788	3426
(ii) Unallocable Income Net of Unallocable Expenditure	(200)	38	(890)
Total Profit Before Tax and Exceptional Items	16859	15957	55595
3. Capital Employed (Segment Assets less Segment Liabilities):			
a) Pharmaceuticals	22871	14244	15849
b) Other Businesses	6144	8006	6040
Total Capital Employed in Segments	29015	22250	21889

Notes:

- 1 Refer note 1 of the aforesaid unaudited financial results for the quarter ended 31st March, 2007
- 2 (i) The Company is organised into two main business segments, namely:
 - Pharmaceuticals comprising of bulk drugs and formulations
 - Others primarily comprising of fine chemicals, diagnostics, laboratory equipment and exports mainly relating to pharmaceuticals.

Animal Health business formed part of the Company's Other Businesses segment in the previous year.

Segments have been identified and reported taking into account, the nature of products and services, the differing risks and returns, the organisation structure, and the internal financial reporting systems.

- (ii) Segment Revenue in each of the above domestic business segments primarily includes sales (net of excise duty), processing charges, consignment sales commission, clinical research and data management and export incentives in the respective segments.
- (iii) Segment Revenue, Results, Assets and Liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.